Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?

In ovariectomized mice, the GLP-1 agonists were found to improve bone density by reducing the inflammation in the bone marrow so there is no contra-indication for a patient with osteoporosis and vertebral fractures to take this class of medications. It is the first weight loss therapy that is not associated with a decrease in bone density.